We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Anti-CRISPR Proteins Increase Safety and Accuracy of Gene Editing

By LabMedica International staff writers
Posted on 21 Dec 2016
Print article
Image: A molecule model of a CRISPR (clustered regularly interspaced short palindromic repeats) and a DNA fragment from E. coli (Photo courtesy of Wikimedia Commons).
Image: A molecule model of a CRISPR (clustered regularly interspaced short palindromic repeats) and a DNA fragment from E. coli (Photo courtesy of Wikimedia Commons).
A set of naturally occurring proteins has been identified that specifically inhibits the action of the CRISP/Cas9 molecular genome-editing complex and thereby greatly increases its accuracy as a tool for manipulating gene expression.

CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location.

The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand. Despite its attractiveness as a gene-editing tool, the technique can inadvertently make excessive or unwanted changes in the genome and create off-target mutations, limiting safety and efficacy in therapeutic applications.

Investigators at the University of Massachusetts Medical School (Worcester, USA) and colleagues at the University of Toronto (Canada) had earlier discovered small proteins encoded by bacteriophages that inhibited the CRISPR-Cas systems of their host bacteria. These "anti-CRISPRs" were specific to type I CRISPR-Cas systems that did not employ the Cas9 protein.

In the current study, the investigators reported that continued research on anti-CRISPRs had led to the identification of three distinct families of anti-CRISPRs that specifically inhibited the CRISPR-Cas9 system of Neisseria meningitidis. They reported in the December 8, 2016, online edition of the journal Cell that these proteins bound directly to N. meningitidis Cas9 (NmeCas9) and could be used as potent inhibitors of genome editing by this system in human cells.

"CRISPR/Cas9 is a good thing because it introduces specific chromosome breaks that can be exploited to create genome edits, but because chromosome breakage can be hazardous, it is possible to have too much of a good thing, or to have it go on for too long," said contributing author Dr. Erik J. Sontheimer, professor in the RNA therapeutics institute at the University of Massachusetts Medical School. "There is a current shortage of reliable ways to turn off Cas9 once it has already been delivered to a cell. If you can trip an off-switch after the correct editing is done, then the problem is relieved. We report the first known natural inhibitors of Cas9 activity. The new paper not only identifies that "off-switch," but it shows that Cas9 inhibitors exist naturally and can be identified and exploited."

"CRISPR is very powerful, but we have to be able to turn it off," said senior author Dr. Alan Davidson, professor of molecular genetics at the University of Toronto. "This is a very fundamental addition to the toolbox, which should give researchers more confidence to use gene editing."

Related Links:
University of Massachusetts Medical School
University of Toronto

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.